Van Beek Jeroen B's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Sep 20, 2021
- Accession no.
- 0000899243-21-036636
- Filed
- Sep 20, 2021
- Trade date
- Feb 17-Sep 17, 2021
- Filing delay
- 215 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions. Open-market sales total $1.41M. It was filed 215 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Van Beek Jeroen BCIK 0001743662 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | Common Stock | SSaleDisposed | −15,196 | $39.65 | −$602,521.4 | 490,134 | Direct | |
| Mar 2, 2021 | Common Stock | SSaleDisposed | −512 | $37.93 | −$19,420.16 | 472,522 | Direct | |
| May 18, 2021 | Common Stock | SSaleDisposed | −15,201 | $22.80 | −$346,582.8 | 457,321 | Direct | |
| Jun 3, 2021 | Common Stock | SSaleDisposed | −508 | $22.87 | −$11,617.96 | 456,813 | Direct | |
| Aug 17, 2021 | Common Stock | SSaleDisposed | −15,205 | $17.82 | −$270,953.1 | 441,608 | Direct | |
| Sep 2, 2021 | Common Stock | SSaleDisposed | −513 | $19.86 | −$10,188.18 | 441,095 | Direct | |
| Sep 17, 2021 | Common Stock | SSaleDisposed | −5,916 | $25.08F4 | −$148,373.28 | 435,179 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.